Liberum Capital Reiterates “Buy” Rating for AstraZeneca plc (AZN)

AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating reaffirmed by equities research analysts at Liberum Capital in a research note issued on Tuesday. They presently have a GBX 5,100 ($62.99) target price on the biopharmaceutical company’s stock. Liberum Capital’s price objective indicates a potential upside of 4.08% from the company’s previous close.

AZN has been the topic of a number of other reports. Berenberg Bank decreased their price target on shares of AstraZeneca plc from GBX 5,500 ($67.93) to GBX 5,450 ($67.31) and set a “buy” rating on the stock in a research note on Tuesday, February 21st. Deutsche Bank AG reaffirmed a “buy” rating and issued a GBX 5,500 ($67.93) price target on shares of AstraZeneca plc in a research note on Wednesday, March 15th. Shore Capital reaffirmed a “hold” rating on shares of AstraZeneca plc in a research note on Tuesday, December 20th. Jefferies Group LLC raised their price target on shares of AstraZeneca plc from GBX 4,800 ($59.28) to GBX 5,250 ($64.84) and gave the company a “buy” rating in a research note on Friday, February 17th. Finally, HSBC Holdings plc reaffirmed a “hold” rating and issued a GBX 4,700 ($58.05) price target on shares of AstraZeneca plc in a research note on Wednesday, January 25th. Four analysts have rated the stock with a sell rating, eight have given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Hold” and an average target price of GBX 5,018.36 ($61.98).

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Shares of AstraZeneca plc (LON:AZN) opened at 4900.00 on Tuesday. AstraZeneca plc has a one year low of GBX 3,680.00 and a one year high of GBX 5,505.00. The stock’s market cap is GBX 62.00 billion. The company has a 50 day moving average price of GBX 4,617.49 and a 200-day moving average price of GBX 4,602.58.

The business also recently announced a dividend, which was paid on Monday, March 20th. Investors of record on Thursday, February 16th were issued a GBX 150.20 ($1.86) dividend. This represents a yield of 3.52%. The ex-dividend date was Thursday, February 16th. This is an increase from AstraZeneca plc’s previous dividend of $68.70.

Your IP Address:

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with our FREE daily email newsletter.

 

Latest News

St. Louis Cardinals Intend to Win National League Central
St. Louis Cardinals Intend to Win National League Central
Los Angeles Angels Defense Helps Complete No-Hitter
Los Angeles Angels Defense Helps Complete No-Hitter
Terry Francona: Attempting to Have Everyone Back from 2016
Terry Francona: Attempting to Have Everyone Back from 2016
New York Yankees Didi Gregorius Injures Shoulder
New York Yankees Didi Gregorius Injures Shoulder
Ian Desmond Remains Positive Despite Hand Surgery
Ian Desmond Remains Positive Despite Hand Surgery
Report: Boat Likely Driven by Jose Fernandez at Time of Crash
Report: Boat Likely Driven by Jose Fernandez at Time of Crash


Leave a Reply

 
© 2006-2017 BBNS.